miR-429通过调控靶基因LRP1抑制乳腺癌细胞增殖
miR-429 Inhibits Proliferation of Breast Cancer Cells by Regulating Target Gene LRP1
DOI: 10.12677/ACM.2022.124384, PDF,   
作者: 纪涵青, 吴 琍*：青岛大学附属医院乳腺病诊疗中心，山东 青岛
关键词: miR-429；乳腺癌；LRP1；抑癌基因；miR-429； Breast Cancer； LRP1； Antioncogene
摘要: 目的：分析miR-429对乳腺癌细胞增殖的抑制作用，通过分析miR-429对其靶基因的调控方式研究miR-429抑制乳腺癌细胞增殖的分子机制。方法：RT-qPCR技术检测乳腺癌组织及体外培养细胞系中miR-429的表达水平；MTT法检测不同miR-429表达水平对乳腺癌细胞系细胞增殖的影响；通过海肾–萤火虫双荧光素酶报告基因活性检测系统、RT-qPCR及Westernblot检测其对靶基因的调控作用。结果：乳腺癌组织及体外培养细胞系中miR-429表达水平显著降低；过表达miR-429显著抑制乳腺癌细胞系细胞增殖；miR-429通过碱基互补的方式与其靶基因LRP1 3’-UTR区域8个碱基结合抑制其表达。结论：miR-429通过调控靶基因LRP1抑制乳腺癌细胞增殖。
Abstract: Objective: The purpose of this study is to analyze the inhibitory effect of miR-429 on the proliferation of breast cancer cells, and study the molecular mechanism of miR-429 by analysing the regulation mode of miR-429 on its target genes. Methods: RT-qPCR is used to detect the relative expression level of miR-429 in breast cancer and the corresponding cancer cells. MTT is used to detect the cell proliferation of breast cancer cells with different expression of miR-429. The double luciferase reporter gene activity detection system, RT-qPCR, and Western blot are used to analyze the regulation of miR-429 on the target gene. Results: miR-429 is significantly down regulated in breast cancer tissues and cultured cell lines compared to the corresponding control. Elevated miR-429 expression inhibits cell proliferation of breast cancer cells. miR-429 inhibits the expression of its target gene LRP1 by binding to eight bases in the 3’-UTR through base complementation. Conclusion: miR-429 inhibits breast cancer cell proliferation by regulating target gene LRP1.
文章引用：纪涵青, 吴琍. miR-429通过调控靶基因LRP1抑制乳腺癌细胞增殖[J]. 临床医学进展, 2022, 12(4): 2671-2682. https://doi.org/10.12677/ACM.2022.124384

参考文献

[1] Liang, Y., Zhang, H., Song, X. and Yang, Q. (2020) Metastatic Heterogeneity of Breast Cancer: Molecular Mechanism and Potential Therapeutic Targets. Seminars in Cancer Biology, 60, 14-27. [Google Scholar] [CrossRef] [PubMed]
[2] Woolston, C. (2015) Breast Cancer. Nature, 527, S101. [Google Scholar] [CrossRef] 
[3] Fahad Ullah, M. (2019) Breast Cancer: Current Perspectives on the Disease Status. In: Ahmad, A., Ed., Breast Cancer Metastasis and Drug Resistance, Vol. 1152, Springer, Cham, 51-64. [Google Scholar] [CrossRef] [PubMed]
[4] Libson, S. and Lippman, M. (2014) A Review of Clinical Aspects of Breast Cancer. International Review of Psychiatry, 26, 4-15. [Google Scholar] [CrossRef] [PubMed]
[5] The Cancer Genome Atlas Network (2012) Comprehensive Molecular Portraits of Human Breast Tumours. Nature, 490, 61-70. [Google Scholar] [CrossRef] [PubMed]
[6] Curigliano, G. and Criscitiello, C. (Eds.) (2014) Successes and Limitations of Targeted Cancer Therapy in Breast Cancer. Progress in Tumor Research, 41, 15-35. [Google Scholar] [CrossRef] [PubMed]
[7] Yao, J., Tan, W., Wu, W., Ye, R., Li, Y. and Chen, Y. (2020) Effects of miR-432 and miR-548c-3p on the Proliferation and Invasion of Osteosarcoma Cells. Journal of BUON, 25, 1562-1568.
[8] Tong, L., Yang, H., Xiong, W., Tang, G., Zu, X. and Qi, L. (2021) Circ_100984-miR-432-3p Axis Regulated c-Jun/YBX-1/beta-Catenin Feedback Loop Promotes Bladder Cancer Progression. Cancer Science, 112, 1429-1442. [Google Scholar] [CrossRef] [PubMed]
[9] Dong, C., Fan, B., Ren, Z., Liu, B. and Wang, Y. (2021) CircSMARCA5 Facilitates the Progression of Prostate Cancer through miR-432/PDCD10 Axis. Cancer Biotherapy & Radiopharmaceuticals, 36, 70-83. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, Y., Xu, W., Zu, M. and Xu, H. (2021) Circular RNA Circ_0021093 Regulates miR-432/Annexin A2 Pathway to Promote Hepatocellular Carcinoma Progression. Anticancer Drugs, 32, 484-495. [Google Scholar] [CrossRef] 
[11] Gong, Y., Zhang, S., Wang, H.X., Huang, Y., Fu, X., Xiang, P., et al. (2022) The Involvement of the circFOXM1-miR-432-Galpha12 Axis in Glioma Cell Proliferation and Aggressiveness. Cell Death Discovery, 8, Article No. 9. [Google Scholar] [CrossRef] [PubMed]
[12] Ye, B., Qiao, K., Zhao, Q., Jiang, Z., Hu, N. and Wang, F. (2022) Tanshinone I Restrains Osteosarcoma Progression by Regulating Circ_0000376/miR-432-5p/BCL2 Axis. Molecular and Cellular Biochemistry, 477, 1-13. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, G. and Yang, H. (2021) CircRNA DUSP16 Knockdown Suppresses Colorectal Cancer Progression by Regulating the miR-432-5p/E2F6 Axis. Cancer Management and Research, 13, 6599-6609. [Google Scholar] [CrossRef] 
[14] Guo, C.M., Liu, S.Q. and Sun, M.Z. (2020) miR-429 as Biomarker for Diagnosis, Treatment and Prognosis of Cancers and Its Potential Action Mechanisms: A Systematic Literature Review. Neoplasma, 67, 215-228. [Google Scholar] [CrossRef] 
[15] Han, Y.T., et al. (2020) miR-429 Mediates Tumor Growth and Metastasis in Colorectal Cancer [Retraction]. American Journal of Cancer Research, 10, 2688.
[16] Xiao, P., Liu, W. and Zhou, H. (2021) miR-429 Promotes the Proliferation of Non-Small Cell Lung Cancer Cells via Targeting DLC-1. Oncology Letters, 22, Article No. 545. [Google Scholar] [CrossRef] [PubMed]
[17] Chen, X., Wang, A.L., Liu, Y.Y., Zhao, C.X., Zhou, X., Liu, H.L., et al. (2020) MiR-429 Involves in the Pathogenesis of Colorectal Cancer via Directly Targeting LATS2. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 5316276. [Google Scholar] [CrossRef] [PubMed]
[18] Yang, J., Liu, Y., He, A., Liu, Y., Wu, J., Liao, X., et al. (2017) Hsa-miR-429 Promotes Bladder Cancer Cell Proliferation via Inhibiting CDKN2B. Oncotarget, 8, 68721-68729. [Google Scholar] [CrossRef] [PubMed]
[19] Zhang, L., Liu, Q., Mu, Q., Zhou, D., Li, H., Zhang, B., et al. (2020) MiR-429 Suppresses Proliferation and Invasion of Breast Cancer via Inhibiting the Wnt/beta-Catenin Signaling Pathway. Thoracic Cancer, 11, 3126-3138. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, X., Yu, X., Zhao, Z., Yuan, Z., Ma, P., Ye, Z., et al. (2020) MicroRNA-429 Inhibits Bone Metastasis in Breast Cancer by Regulating CrkL and MMP-9. Bone, 130, Article ID: 115139. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, C., Ju, H., Shen, C. and Tong, Z. (2015) miR-429 Mediates Delta-Tocotrienol-Induced Apoptosis in Triple-Negative Breast Cancer Cells by Targeting XIAP. International Journal of Clinical and Experimental Medicine, 8, 15648-15656.
[22] Ye, Z.B., Ma, G., Zhao, Y.H., Xiao, Y., Zhan, Y., Jing, C., et al. (2015) miR-429 Inhibits Migration and Invasion of Breast Cancer Cells in Vitro. International Journal of Oncology, 46, 531-538. [Google Scholar] [CrossRef] [PubMed]
[23] Polyak, K. (2007) Breast Cancer: Origins and Evolution. Journal of Clinical Investigation, 117, 3155-3163. [Google Scholar] [CrossRef] 
[24] Karagiannis, G.S., Goswami, S., Jones, J.G., Oktay, M.H. and Condeelis, J.S. (2016) Signatures of Breast Cancer Metastasis at a Glance. Journal of Cell Science, 129, 1751-1758. [Google Scholar] [CrossRef] [PubMed]
[25] Castaneda-Gill, J.M. and Vishwanatha, J.K. (2016) Antiangiogenic Mechanisms and Factors in Breast Cancer Treatment. Journal of Carcinogenesis, 15, 1. [Google Scholar] [CrossRef] [PubMed]
[26] Ahmad, A. (2013) Pathways to Breast Cancer Recurrence. International Scholarly Research Notices, 2013, Article ID: 290568. [Google Scholar] [CrossRef] [PubMed]
[27] Fouad, Y.A. and Aanei, C. (2017) Revisiting the Hallmarks of Cancer. American Journal of Cancer Research, 7, 1016-1036.
[28] Jin, L., Han, B., Siegel, E., Cui, Y., Giuliano, A. and Cui, X. (2018) Breast Cancer Lung Metastasis: Molecular Biology and Therapeutic Implications. Cancer Biology & Therapy, 19, 858-868. [Google Scholar] [CrossRef] [PubMed]
[29] Correia de Sousa, M., Gjorgjieva, M., Dolicka, D., Sobolewski, C. and Foti, M. (2019) Deciphering miRNAs’ Action through miRNA Editing. International Journal of Molecular Sciences, 20, Article No. 6249. [Google Scholar] [CrossRef] [PubMed]
[30] Fabian, M.R. and Sonenberg, N. (2012) The Mechanics of miRNA-Mediated Gene Silencing: A Look under the Hood of miRISC. Nature Structural & Molecular Biology, 19, 586-593. [Google Scholar] [CrossRef] [PubMed]
[31] He, B., Zhao, Z., Cai, Q., Zhang, Y., Zhang, P., Shi, S., et al. (2020) miRNA-Based Biomarkers, Therapies, and Resistance in Cancer. International Journal of Biological Sciences, 16, 2628-2647. [Google Scholar] [CrossRef] [PubMed]
[32] Iorio, M.V., Ferracin, M., Liu, C.G., Veronese, A., Spizzo, R., Sabbioni, S., et al. (2005) MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 65, 7065-7070. [Google Scholar] [CrossRef] 
[33] Wang, W. and Luo, Y.P. (2015) MicroRNAs in Breast Cancer: Oncogene and Tumor Suppressors with Clinical Potential. Journal of Zhejiang University: SCIENCE B, 16, 18-31. [Google Scholar] [CrossRef] 
[34] Jiang, D. and Zhao, N. (2006) A Clinical Prognostic Prediction of Lymph Node-Negative Breast Cancer by Gene Expression Profiles. Journal of Cancer Research and Clinical Oncology, 132, 579-587. [Google Scholar] [CrossRef] [PubMed]
[35] Shen, J., Stass, S.A. and Jiang, F. (2013) MicroRNAs as Potential Biomarkers in Human Solid Tumors. Cancer Letters, 329, 125-136. [Google Scholar] [CrossRef] [PubMed]
[36] Wen, B., Zhu, R., Jin, H. and Zhao, K. (2021) Differential Expression and Role of miR-200 Family in Multiple Tumors. Analytical Biochemistry, 626, Article ID: 114243. [Google Scholar] [CrossRef] [PubMed]
[37] Cavallari, I., Ciccarese, F., Sharova, E., Urso, L., Raimondi, V., Silic-Benussi, M., et al. (2021) The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers. Cancers, 13, Article No. 5874. [Google Scholar] [CrossRef] [PubMed]
[38] Mao, Y., Chen, W., Wu, H., Liu, C., Zhang, J. and Chen, S. (2020) Mechanisms and Functions of MiR-200 Family in Hepatocellular Carcinoma. OncoTargets and Therapy, 13, 13479-13490. [Google Scholar] [CrossRef] 
[39] Koutsaki, M., Libra, M., Spandidos, D.A. and Zaravinos, A. (2017) The miR-200 Family in Ovarian Cancer. Oncotarget, 8, 66629-66640. [Google Scholar] [CrossRef] [PubMed]
[40] Peng, L., Fu, J. and Ming, Y. (2018) The miR-200 Family: Multiple Effects on Gliomas. Cancer Management and Research, 10, 1987-1992. [Google Scholar] [CrossRef] 
[41] Xue, B., Chuang, C.H., Prosser, H.M., Fuziwara, C.S., Chan, C., Sahasrabudhe, N., et al. (2021) miR-200 Deficiency Promotes Lung Cancer Metastasis by Activating Notch Signaling in Cancer-Associated Fibroblasts. Genes & Development, 35, 1109-1122. [Google Scholar] [CrossRef] [PubMed]
[42] Liu, C., Hu, W., Li, L.L., Wang, Y.X., Zhou, Q., Zhang, F., et al. (2018) Roles of miR-200 Family Members in Lung Cancer: More than Tumor Suppressors. Future Oncology, 14, 2875-2886. [Google Scholar] [CrossRef] [PubMed]
[43] Gao, Y., Zhang, W., Liu, C. and Li, G. (2019) miR-200 Affects Tamoxifen Resistance in Breast Cancer Cells through Regulation of MYB. Scientific Reports, 9, Article ID: 18844. [Google Scholar] [CrossRef] [PubMed]
[44] Kozak, J., Jonak, K. and Maciejewski, R. (2020) The Function of miR-200 Family in Oxidative Stress Response Evoked in Cancer Chemotherapy and Radiotherapy. Biomedicine & Pharmacotherapy, 125, Article ID: 110037. [Google Scholar] [CrossRef] [PubMed]
[45] Zhang, H.F., Xu, L.Y. and Li, E.M. (2014) A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets. Current Pharmaceutical Design, 20, 1896-1903. [Google Scholar] [CrossRef] [PubMed]
[46] Bartel, D.P. (2009) MicroRNAs: Target Recognition and Regulatory Functions. Cell, 136, 215-233. [Google Scholar] [CrossRef] [PubMed]
[47] Fabian, M.R., Sonenberg, N. and Filipowicz, W. (2010) Regulation of mRNA Translation and Stability by MicroRNAs. Annual Review of Biochemistry, 79, 351-379. [Google Scholar] [CrossRef] [PubMed]
[48] Wujak, L., Schnieder, J., Schaefer, L. and Wygrecka, M. (2018) LRP1: A Chameleon Receptor of Lung Inflammation and Repair. Matrix Biology, 68-69, 366-381. [Google Scholar] [CrossRef] [PubMed]
[49] Boulagnon-Rombi, C., Schneider, C., Leandri, C., Jeanne, A., Grybek, V., Bressenot, A.M., et al. (2018) LRP1 Expression in Colon Cancer Predicts Clinical Outcome. Oncotarget, 9, 8849-8869. [Google Scholar] [CrossRef] [PubMed]
[50] Feng, C., Ding, G., Ding, Q. and Wen, H. (2018) Overexpression of Low Density Lipoprotein Receptor-Related Protein 1 (LRP1) Is Associated with Worsened Prognosis and Decreased Cancer Immunity in Clear-Cell Renal Cell Carcinoma. Biochemical and Biophysical Research Communications, 503, 1537-1543. [Google Scholar] [CrossRef] [PubMed]
[51] Meng, H., Chen, G., Zhang, X., Wang, Z., Thomas, D.G., Giordano, T.J., et al. (2011) Stromal LRP1 in Lung Adenocarcinoma Predicts Clinical Outcome. Clinical Cancer Research, 17, 2426-2433. [Google Scholar] [CrossRef] 

为你推荐